A Phase 3 interventional study of co-administration of cefepime and nacubactam and co-administration of aztreonam and nacubactam in Complicated Urinary Tract Infection, Acute Pyelonephritis and cUTI, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 61 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.
Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).
79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.
This study's enrollment of 614 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.
Browse Pyelonephritis studies →Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)
Drug: co-administration of cefepime and nacubactam
co-administration of 2 g aztreonam and 1 g nacubactam q8h (60 min. infusion)
Drug: co-administration of aztreonam and nacubactam
combination of 1 g imipenem/1 g cilastatin q8h (60 min. infusion)
Drug: imipenem/cilastatin
Drug pages: Cefepime · Nacubactam
2 g cefepime and 1 g nacubactam
Drug pages: Aztreonam · Nacubactam
2 g aztreonama and 1 g nacubactam
Drug pages: Imipenem · Cilastatin
1 g imipenem/1 g cilastatin
Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication.
Time frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]
Proportion of Patients Who Achieve Composite Clinical and Microbiological Outcome
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Proportion of Patients With a Clinical Outcome of Cure
Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Proportion of Patients With a Microbiological Outcome of Eradication
Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Proportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia.
Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Proportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Proportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. For cUTI/AP,Assessment is done by the same way as "Proportion of patients who achieve composite clinical and microbiological outcome". For secondary bacteremia, assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Proportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
A total of 678 patients were screened at 66 sites in 9 countries and 614 patients were radomized.
| Milestone | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Started | 309 | 154 | 151 |
| Treated | 307 | 152 | 151 |
| Completed study drug | 290 | 147 | 143 |
| Completed | 284 | 144 | 139 |
| Not completed | 25 | 10 | 12 |
| Withdrew: Adverse event | 6 | 1 | 1 |
| Withdrew: Physician decision | 4 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 3 |
| Withdrew: Ineligibility after the start of the study | 4 | 1 | 0 |
| Withdrew: Subject non-compliance | 4 | 0 | 4 |
| Withdrew: Grew only a gram-negative organism resistant to imipenem and/or meropenem | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Required use of prohibited concomitant medications | 1 | 0 | 0 |
| Withdrew: Significant prolongation of the qt/qtc interval | 0 | 1 | 0 |
| Withdrew: Other reason | 3 | 3 | 3 |
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population | 176 | 81 | 64 |
Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Composite clinical and microbiological success at EA (Early Assessment visit) | 201 | 110 | 96 |
| Composite clinical and microbiological success at EOT (End of Treatment visit) | 199 | 102 | 94 |
| Composite clinical and microbiological success at FUP (Follow-up visit) | 147 | 73 | 65 |
| Composite clinical and microbiological success at TOC by baseline pathogen: Escherichia coli | 135 | 62 | 45 |
| Composite clinical and microbiological success at TOC by baseline pathogen: Klebsiella pneumoniae | 27 | 11 | 9 |
| Composite clinical and microbiological success at EOT by baseline pathogen: Escherichia coli | 151 | 81 | 66 |
| Composite clinical and microbiological success at EOT by baseline pathogen: Klebsiella pneumoniae | 30 | 10 | 16 |
| Composite clinical and microbiological success at FUP by baseline pathogen: Escherichia coli | 112 | 57 | 44 |
| Composite clinical and microbiological success at FUP by baseline pathogen: Klebsiella pneumoniae | 20 | 9 | 11 |
Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Clinical outcome of cure at EA | 9 | 4 | 2 |
| Clinical outcome of cure at EOT | 204 | 106 | 100 |
| Clinical outcome of cure at TOC | 195 | 103 | 92 |
| Clinical outcome of cure at FUP | 188 | 98 | 89 |
| Clinical outcome of cure at EA by baseline pathogen: Escherichia coli | 5 | 3 | 1 |
| Clinical outcome of cure at EA by baseline pathogen: Klebsiella pneumoniae | 2 | 1 | 0 |
| Clinical outcome of cure at EOT by baseline pathogen: Escherichia coli | 155 | 84 | 71 |
| Clinical outcome of cure at EOT by baseline pathogen: Klebsiella pneumoniae | 31 | 11 | 16 |
| Clinical outcome of cure at TOC by baseline pathogen: Escherichia coli | 148 | 82 | 67 |
| Clinical outcome of cure at TOC by baseline pathogen: Klebsiella pneumoniae | 30 | 11 | 13 |
| Clinical outcome of cure at FUP by baseline pathogen: Escherichia coli | 143 | 78 | 62 |
| Clinical outcome of cure at FUP by baseline pathogen: Klebsiella pneumoniae | 28 | 11 | 15 |
Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Microbiological outcome of eradication at EA | 205 | 112 | 97 |
| Microbiological outcome of eradication at EOT | 203 | 105 | 95 |
| Microbiological outcome of eradication at TOC | 184 | 83 | 67 |
| Microbiological outcome of eradication at FUP | 157 | 75 | 68 |
| Microbiological outcome of eradication at EA by baseline pathogen: Escherichia coli | 155 | 89 | 71 |
| Microbiological outcome of eradication at EA by baseline pathogen: Klebsiella pneumoniae | 30 | 12 | 13 |
| Microbiological outcome of eradication at EOT by baseline pathogen: Escherichia coli | 154 | 83 | 67 |
| Microbiological outcome of eradication at EOT by baseline pathogen: Klebsiella pneumoniae | 30 | 11 | 16 |
| Microbiological outcome of eradication at TOC by baseline pathogen: Escherichia coli | 141 | 63 | 47 |
| Microbiological outcome of eradication at TOC by baseline pathogen: Klebsiella pneumoniae | 27 | 11 | 10 |
| Microbiological outcome of eradication at FUP by baseline pathogen: Escherichia coli | 119 | 58 | 46 |
| Microbiological outcome of eradication at FUP by baseline pathogen: Klebsiella pneumoniae | 22 | 9 | 12 |
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Proportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline | 12 | 8 | 6 |
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Proportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline | 12 | 8 | 6 |
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. For cUTI/AP,Assessment is done by the same way as "Proportion of patients who achieve composite clinical and microbiological outcome". For secondary bacteremia, assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Proportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline | 11 | 4 | 2 |
Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.
| Participants | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Proportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC | 12 | 8 | 6 |
Collected over Up to follow-up visit (maximum Day 30). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cefepime/Nacubactam | 1/306 (0.3%) | 6/306 (2%) | 100/306 (32.7%) |
| Aztreonam/Nacubactam | 0/152 (0%) | 4/152 (2.6%) | 45/152 (29.6%) |
| Imipenem/Cilastatin | 0/150 (0%) | 5/150 (3.3%) | 65/150 (43.3%) |
| Event | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| PyrexiaGeneral disorders | 0/306 | 0/152 | 2/150 |
| Urinary tract infectionInfections and infestations | 1/306 | 2/152 | 1/150 |
| OrchitisInfections and infestations | 0/306 | 0/152 | 1/150 |
| ChillsGeneral disorders | 0/306 | 0/152 | 1/150 |
| HyperthermiaGeneral disorders | 0/306 | 0/152 | 1/150 |
| Renal failureRenal and urinary disorders | 0/306 | 0/152 | 1/150 |
| Acute kidney injuryRenal and urinary disorders | 0/306 | 1/152 | 0/150 |
| Biliary colicHepatobiliary disorders | 0/306 | 1/152 | 0/150 |
| COVID-19Infections and infestations | 1/306 | 0/152 | 0/150 |
| Disease progressionGeneral disorders | 1/306 | 0/152 | 0/150 |
| Event | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin |
|---|---|---|---|
| Any AEs with frequency less than 2%General disorders | 42/306 | 13/152 | 17/150 |
| NauseaGastrointestinal disorders | 5/306 | 1/152 | 10/150 |
| HeadacheNervous system disorders | 10/306 | 8/152 | 6/150 |
| Asymptomatic bacteriuriaInfections and infestations | 3/306 | 7/152 | 5/150 |
| DiarrhoeaGastrointestinal disorders | 14/306 | 3/152 | 6/150 |
| VomitingGastrointestinal disorders | 2/306 | 1/152 | 5/150 |
| ConstipationGastrointestinal disorders | 6/306 | 3/152 | 4/150 |
| RashSkin and subcutaneous tissue disorders | 2/306 | 2/152 | 4/150 |
| Abdominal pain upperGastrointestinal disorders | 1/306 | 1/152 | 3/150 |
| PyrexiaGeneral disorders | 4/306 | 2/152 | 3/150 |
m-MITT population
| Age, Categorical(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 99 | 42 | 41 | 182 |
| >=65 years | 115 | 70 | 64 | 249 |
| Sex: Female, Male(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Female | 103 | 51 | 49 | 203 |
| Male | 111 | 61 | 56 | 228 |
| Race/Ethnicity, Customized(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Race, Customized — Asian-Japanese | 12 | 6 | 5 | 23 |
| Race, Customized — Asian-Chinese | 23 | 9 | 7 | 39 |
| Race, Customized — Asian-other | 0 | 1 | 0 | 1 |
| Race, Customized — White | 179 | 96 | 93 | 368 |
| Age, Continuous(years) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Mean | 63.6 ± 14.83 | 66.4 ± 14.04 | 65.5 ± 15.57 | 64.8 ± 14.83 |
| Age, Customized(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Age, Customized — <65 years | 99 | 42 | 41 | 182 |
| Age, Customized — 65 - 74 Years | 62 | 36 | 32 | 130 |
| Age, Customized — >=75 years | 53 | 34 | 32 | 119 |
| Race/Ethnicity, Customized(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Ethnicity, Customized — Hispanic or Latino | 1 | 0 | 2 | 3 |
| Ethnicity, Customized — Not Hispanic or Latino | 212 | 112 | 103 | 427 |
| Ethnicity, Customized — Unknown | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Japan | 12 | 6 | 5 | 23 |
| China | 23 | 10 | 7 | 40 |
| Other | 179 | 96 | 93 | 368 |
| Primary infection type collected in eCRF(Participants) | Cefepime/Nacubactam | Aztreonam/Nacubactam | Imipenem/Cilastatin | Total |
|---|---|---|---|---|
| Complicated Urinary Tract Infection (cUTI) | 137 | 76 | 73 | 286 |
| Acute Uncomplicated Pyelonephritis (AP) | 77 | 36 | 32 | 145 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2023 to primary completion in Nov 2024, 17 months.
Results were first posted in Nov 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cefepime · Nacubactam · Aztreonam
Meiji Seika Pharma Co., Ltd.